Who we are
Viralgen is a CDMO born as a joint venture between Askbio and Columbus Venture Partners, combining decades of technology and drug development experience in multiple platforms to support best-in-class service offerings to the gene therapy market.
Viralgen was created in 2017 in response to the unmet need for manufacturing of gene therapies. Our goal was to help broaden the access to these life-saving therapeutics and contribute to the advancement of health and human welfare around the world.
We specialize in the production of rAAV viral vectors. Our optimized facility in San Sebastian, Spain maximizes throughput and efficiency of our proprietary Pro10™ suspension manufacturing platform. This enables industry-leading scalability, reproducibility, and speed to market.
Through our superior technology platform, we deliver industry-leading titers and cGMP-certified quality for all AAV serotypes to our client partners, optimize the cost-of-goods and accelerate clinical development and commercialization of life-saving genetic medicines.
Asklepios BioPharmaceutical, Inc. (AskBio) was founded in 2003 by Richard Jude Samulski, PhD, and Sheila Mikhail in Chapel Hill, North Carolina to take advantage of the deep gene therapy resources in the Research Triangle Park area. AskBio has since set the standard for gene therapy clinical development including a deep portfolio of intellectual property in gene therapy for multiple disease and an advanced manufacturing process.
AskBio has established and formed industry alliances for multiple spin out companies and continues to pursue new gene therapy technologies and treatments. Among those spin out are NanoCor Therapeutics (partnered with Medtronics to develop treatment for heart failure), Chatham Therapeutics (sold to Baxter to develop hemophilia treatments), and Bamboo Therapeutics (sold to Pfizer to develop cures for rare neuromuscular diseases and muscular dystrophy).
About Columbus Venture Partners
Columbus Venture Partners is a Spanish investment Management Company with an investment strategy focused on the early-stage and high growth opportunities of biotechnology, medical technology, pharmaceuticals and healthcare industries in Spain. Its team of professionals combines a solid scientific, medical and business knowledge with an extensive experience in the establishment and investment of companies to accelerate merchandising.
The Columbus investment team has more than 75 years of professional experience with venture capital investments in pharmaceutical and biotechnology companies and invests through the COLUMBUS INNVIERTE Life Science Fund, FCR.
Almost 30 years of experience working in healthcare and the biopharmaceutical industry. Since 2009, Mr. Garcia has focused on life science venture capital investing, where he focuses on private company investments in the biopharmaceutical, life science and medical technology sectors. Mr. García received a bachelor's in mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and an MBA from ICADE (Spain). He's also president and founder of Columbus Venture Partner, and co-founder of Columbus Children's Foundation.
Comes to Viralgen with almost 20 years of experience in biotech pharmaceutical field, mainly leading teams in the design, construction and start up of late clinical phases and commercial manufacturing facilities. She holds a Bachelor Degree in Analytical Chemistry from Santiago of Compostela University, a Master in Safety, Health and Environment by University of Vigo, MBA by IESIDE and Master in Neuroscience, Emotional Intelligence and Coaching by Isabel I University (Burgos).
Patrick Barry is Vice President of Business Development at Viralgen since March 2022. Patrick has more than 20 years of experience in the Viral and Gene Therapy (VGT) industry for both testing, production and process development. Prior to joining Viralgen Patrick spent over 20 years with Millipore Sigma/BioReliance in increasing commercial roles. These roles included numerous regulatory and testing programs from preclinical through commercial programs for both VGT and biologics molecules. Patrick has a M.Sc. from the University of Massachusetts and an MBA from Babson Coll.
Jimmy Vanhove brings extensive experience in strategy, operational management, and digital transformation in the biotech/pharma industry. He has held various leadership positions with increased responsibility in manufacturing and strategy consulting at multinational companies like GSK Vaccines, Bayer, and Roland Berger. Before joining Viralgen in 2021, he worked as the chief of staff for Bayer Pharma Product Supply. Jimmy holds a master’s degree in Bioscience Engineering from KU Leuven, and in General Management from Vlerick Business School. He has also received executive training in Digital Transformation at IMD, Lausanne, and Executive Management Development at IESE business school, Barcelona.
Carmen has and brings a solid experience and training in senior management, marketing and communication shaped by both multinational companies and her own ventures within her specialty. Carmen is the president of the Mentor Club of the Faculty of Economics at the University of Valencia and has also been a representative of Peace at the UN for the Rotary Club of Spain. She is heavily involved and collaborates regularly with various NGOs and non-profit organizations. Carmen holds a BSc in Business Administration from the Faculty of Economics of the University of Valencia and a MSc in International Trade and Management from ESIC Business & Marketing School Valencia. She has also completed the Executive Development Program at IESE Business School from the University of Navarra along with the management coaching program.
Highly experienced lawyer specialized in People Management. Over the past 25 years, she has worked on Team and Management Development, gaining expertise in a variety of international companies dedicated to various fields including the financial, industrial, health, distribution and aeronautics industries. She also has a strong academic foundation: a degree in law and a master’s degree in human resources. After searching for a company committed to human development where challenges are available, Kontxi comes to Viralgen as Human Resources Director to contribute to the business growth.
With a degree in Business Administration and Management from the Public University of Navarra, over 15 years Marta has worked and gained expertise in the field of financial auditing, strategic consulting and financial control. She comes to Viralgen with the aim of ensuring the correct use of the company's financial resources and for its well-being and economic stability.
Philippe Moullier, MD, PhD
Chief Scientific Officer Europe of Asklepios Biopharmaceutical (AskBio)
Joined Viralgen in May 2017 after working as collaborator of Bamboo Therapeutics from March 2015 through July 2016. Philippe Moullier was the founder and, until Dec 2016, the Director of the research INSERM Unit UMR 1089 entitled « Translational Gene Therapy for Retinal and Neuromuscular Diseases » at the University of Nantes, France. In January 2018, Philippe Moullier was appointed as Chief Development Officer at Viralgen VC in San Sebastian, Spain. Philippe also serves as the Chief Scientific Officer for Askbio Europe. His dual appointments allow the reinforcement of the US-Spanish strategic partnership.